~20% annual revenue growth for FY26
Management remains confident despite Q3's 11% growth, with larger contribution from newly launched products expected in Q4 and ~₹284 crore revenue needed to meet target.
SUPRIYA / guidance tracker
Keep management guidance in view.
Supriya Lifescience · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
EBITDA margins of 33-35%
Management maintained guidance despite near-term pressure from new product scale-ups in semi-regulated markets, expecting normalization as products migrate to regulated markets.
₹1,000 crore revenue target for FY27
Driven by regulated market scale-up of existing portfolio, 3-4 new product launches annually, and Ambernath CDMO facility contribution starting next year.
Ambernath facility EBITDA positive by Q3 FY27
Commercial revenue begins Q4 FY26, with meaningful contributions expected from H2 FY27; full EBITDA positive status by Q3 FY27.
FY27 Revenue Target: Rs 1,000 crore
Company reiterates approximately 20% annual revenue growth guidance with the Rs 1,000 crore milestone achievable in FY27, underpinned by robust pipeline and planned 3-4 product launches annually.
EBITDA Margin: 33-35% Range
Management guides for sustained EBITDA margins within the 33-35% band, explaining that new product scale-ups initially serve semi-regulated markets before maturing to regulated markets over 2-3 years.
Patal Ganga Phase One Capex: Rs 200 Crore
Phase one development includes 2 API/advanced intermediate blocks and 2 formulation blocks; all clearances received, groundbreaking to begin in FY27.
Annual New Product Launches: 3-4 Per Year
FY27 will see strengthening of anesthetics and ADHD portfolios with 2 new launches; contrast media launch deferred to H2 FY27 for process optimization.